Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 3,096 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: M.D. Anderson Cancer Center Clear all
Recruiting No phase listed Observational

Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix

NCT05046080
View directory record Official record
Conditions
Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type
Interventions
Electronic Health Record Review, Laboratory Biomarker Analysis
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 24, 2026, 2:53 PM EDT
Completed Phase 1 Interventional

Fluorescent Dyes for Lymph Node Mapping

NCT01095913
View directory record Official record
Conditions
Breast Cancer
Interventions
Indocyanine green (ICG)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 24, 2026, 2:53 PM EDT
Completed No phase listed Observational

Electroencephalographic Changes Under General Anesthesia in Patients With Gynecologic Cancers With and Without History of Chemotherapy

NCT04593550
View directory record Official record
Conditions
Malignant Female Reproductive System Neoplasm
Interventions
Biospecimen Collection, BrainCheck Cognitive Assessment, Cognitive Assessment, Electroencephalography
Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 24, 2026, 2:53 PM EDT
Recruiting Phase 2 Interventional

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

NCT05365035
View directory record Official record
Conditions
Myelodysplastic Syndromes, Myeloproliferative Chronic Myelomonocytic Leukemia
Interventions
Cladribine, Cytarabine, Venetoclax, Azacitidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 24, 2026, 2:53 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients

NCT01906008
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Minocycline, Placebo, Questionnaires, Sensory Test
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 24, 2026, 2:53 PM EDT
Completed Phase 2 Interventional

Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach

NCT00002682
View directory record Official record
Conditions
Lymphoma
Interventions
Amoxicillin, Bismuth Subsalicylate, Clarithromycin, Metronidazole Hydrochloride, Omeprazole, Tetracycline Hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
2
States / cities
Orlando, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 24, 2026, 2:53 PM EDT
Terminated Phase 2 Interventional Results available

Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia

NCT00623974
View directory record Official record
Conditions
Hypocalcemia
Interventions
Teriparatide (Forteo), Calcium, Calcitriol
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 24, 2026, 2:53 PM EDT
Completed Phase 2 Interventional Results available

Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia

NCT02530515
View directory record Official record
Conditions
Anemia, Cancer Fatigue, Chronic Lymphocytic Leukemia, Fever, Infectious Disorder, Lymphadenopathy, Lymphocytosis, Night Sweats, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Richter Syndrome, Secondary Malignant Neoplasm, Thrombocytopenia, Weight Loss
Interventions
Ex Vivo-activated Autologous Lymph Node Lymphocytes, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 24, 2026, 2:53 PM EDT
Terminated Phase 2 Interventional Results available

Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)

NCT01253460
View directory record Official record
Conditions
Leukemia
Interventions
Cyclophosphamide, Rituximab, Sapacitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 24, 2026, 2:53 PM EDT
Active, not recruiting Phase 2 Interventional

Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma

NCT04189757
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Acalabrutinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 24, 2026, 2:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

NCT02464657
View directory record Official record
Conditions
Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Nivolumab, Idarubicin, Cytarabine, Solu-medrol, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 24, 2026, 2:53 PM EDT
Completed Phase 1 Interventional

Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer

NCT03290937
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Cetuximab, Irinotecan Hydrochloride, Pharmacodynamic Study, Utomilumab
Biological · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 24, 2026, 2:53 PM EDT
Recruiting Not applicable Interventional

Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.

NCT05649072
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer, Colorectal Cancer
Interventions
Genetic Testing and Counseling, Screening Form
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 24, 2026, 2:53 PM EDT
Terminated Phase 2 Interventional Results available

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02923739
View directory record Official record
Conditions
Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Bevacizumab, Emactuzumab, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study
Biological · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Voorhees Township, New Jersey • Dallas, Texas • Houston, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 24, 2026, 2:53 PM EDT
Completed Phase 2 Interventional Results available

Intraoperative Aromatherapy Versus Placebo for Port-a-Cath Placement Under Monitored Anesthesia Care. A Randomized Controlled Trial

NCT05328973
View directory record Official record
Conditions
Cancer Pain
Interventions
ELEQUIL
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 24, 2026, 2:53 PM EDT
Completed No phase listed Observational

Effectiveness of Bronchoscopic Interventions for Malignant Airway Obstruction

NCT03326570
View directory record Official record
Conditions
Lung Cancer
Interventions
Medical Data Collection
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 24, 2026, 2:53 PM EDT
Active, not recruiting No phase listed Observational

Clinical Data Collection in Studying Clinical Factors Associated With Post-Surgery Chronic Opioid Use in Patients With Head and Neck Cancers

NCT03888651
View directory record Official record
Conditions
Head and Neck Carcinoma
Interventions
Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 24, 2026, 2:53 PM EDT
Terminated Phase 2 Interventional Results available

Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure

NCT02906696
View directory record Official record
Conditions
Blasts Under 15 Percent of Bone Marrow Nucleated Cells, Blasts Under 15 Percent of Peripheral Blood White Cells, Blasts Under 30 Percent of Bone Marrow Nucleated Cells, Blasts Under 30 Percent of Peripheral Blood White Cells, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions
Bosutinib, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 24, 2026, 2:53 PM EDT
Completed Not applicable Interventional Results available

Second Generation LMA Versus Endotracheal Tube in Obese Patients

NCT03748342
View directory record Official record
Conditions
Obese, Endotracheal Tube, Laryngeal Mask Airway
Interventions
Second-Generation Laryngeal Mask Airway
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 24, 2026, 2:53 PM EDT
Active, not recruiting Phase 1 Interventional

Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia

NCT07411586
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Ziftomenib, Olutasidenib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 24, 2026, 2:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Cancer Symptoms on Caregivers

NCT00351988
View directory record Official record
Conditions
Psychosocial
Interventions
Phenomenological Interviews, Quantitative Interviews
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2022
U.S. locations
4
States / cities
Miami, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 24, 2026, 2:53 PM EDT
Completed Phase 1 Interventional

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

NCT01531361
View directory record Official record
Conditions
Advanced Malignant Neoplasm, BRAF Gene Mutation, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
Interventions
Crizotinib, Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate, Vemurafenib
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 24, 2026, 2:53 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

NCT05110742
View directory record Official record
Conditions
Hematological Malignancy
Interventions
Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 24, 2026, 2:53 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluation of the Bio-Seal Biopsy Track Plug

NCT00527722
View directory record Official record
Conditions
Lung Cancer
Interventions
Bio-Seal Track Plug, No lung plug
Device · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 24, 2026, 2:53 PM EDT